Nimble Science unveils “unprecedented” GI diagnostics platform with ingestible capsule device

Nimble Science, a precision medicine company offering biopharma and digestive health companies access to novel gastrointestinal (GI) health data, introduces its data platform designed to “transform” diagnostics across various healthcare fields, including GI, neurological, metabolic, consumer and animal health. 

The new SIMBA GI Health Data Platform links with Nimble Science’s proprietary SIMBA Capsule. The “first-in-class” device that collects and preserves “precise, high-quality” samples directly from the small intestine when ingested.

Coinciding with the launch, Nimble Science welcomes professor Eran Segal, a renowned computational biologist from the Weizmann Institute of Science, Israel, to its Scientific Advisory Board. He holds expertise in personalized medicine, nutrition and the complex interplay between genetics, the microbiome and health.

Professor Segal will provide strategic guidance as the company pioneers solutions that leverage its growing database of precision intestinal data. “The small intestinal microbiome is a critical frontier in understanding and improving human health,” he underscores.

“Nimble’s innovative platform offers an unprecedented opportunity to map microorganisms in this vital region at scale, shedding light on disease mechanisms and enabling the development of transformative diagnostics and therapeutics and targeted interventions for a vast range of health conditions.”

“First-in-class” ingestible diagnostics

The SIMBA Capsule has been integrated into over 19 global clinical studies, delivering solutions to customers evaluating disease conditions and therapeutic product interaction. 

The capsule featured in a clinical trial by probiotics R&D giant Lallemand Health Solutions, which assessed the efficacy of the Bacillus subtilis R0179 strain in alleviating symptoms of Small Intestinal Bacterial Overgrowth.

The SIMBA Capsule has been integrated into over 19 global clinical studies.The new data platform now offers users data quality indexing and access to insights derived from a growing repository of matched metagenomic data sets from healthy and disordered small intestinal samples.

“The ability to provide high quality, scalable data insights is a turning point in healthcare innovation for Nimble and our partners, and opens the door to discoveries previously out of reach,” says Sabina Bruehlmann, co-founder and CEO of Nimble Science.

“The addition of professor Eran Segal to the Scientific Advisory Board, speaks to the quality of the SIMBA Capsule data and its massive potential for health innovation.”

Building upon the successful launch, Nimble Science is actively expanding partnerships across the healthcare, life sciences and consumer product sectors to further the potential of its multi-omic data.

Leading life science investors, including Fusion Fund, Seventure Partners, Joyance Partners and Ki Tua Fund support the company.

Advancing precision

Global interest in precision healthcare and nutrition is ramping up, with Hologram Sciences recently speaking on AI’s potential to further accelerate the field at the 2024 World Economic Forum. Nutrition Insight caught up with the company’s co-founder and CEO about how its AI software optimizes dietary plans to an individual’s health and sustainability considerations.

In other developments in personalized dietary interventions, organic micronutrient start-up Biovit received £1.5 million (US$2,005,950) from Innovate UK last September to create the world’s “most accurate” AI-driven personalized nutrition system, set for a UK National Health Service trial this year.

Meanwhile, US nutrigenomic platform GenoPalate partnered with employee benefits company ThrivePass in the same month to offer access to personalized nutritional insights based on a person’s DNA. These include dietitian-crafted recipe bundles and personalized vitamin offerings to enhance individual wellness plans.

Responding to a need to further democratize access to personalized nutrition to treat and manage chronic diseases, US-based digital platform Heali developed a “food-as-medicine” app demonstrating clinical-grade health outcomes. The company netted US$3 million in seed funding for its app from the nation’s Center for Disease Control and Prevention.